[Pompe disease or type 2 glycogenosis].

نویسندگان

  • S Hansoul
  • B Derkenne
  • B Daron
  • H Keutgen
  • J Senterre
چکیده

We report the case of a rapidly progressing respiratory failure of a three-month old infant, who shows a cardiomyopathy with left ventricule hypertrophy leading to a Pompe's disease diagnosis. This type 2 glycogenosis will be confirmed by the enzymatic study of the hepatocytes. It is a genetic pathology associated with a deficient activity of the acid maltase resulting in a intralysosomial accumulation of glycogen. The most generally responsible mutations are: delta 18 et delta 525. Prognosis is quite bad with a progressive deterioration of the heart, brain and muscular functions causing death at around 4 to 8 months. Type 2 glycogenosis may be diagnosed before birth through enzymatic study of a material collected through an amniocentesis or a biopsy on chorionic villi, and through DNA analysis. Curative treatment is still under study, but two main research orientations are being developed: genic therapy using viral vector and the correction of the enzymatic deficiency thanks to the synthesis of alpha glucosidase modified to specially get affixed to the heart and muscular cells. Both techniques have already show some encouraging results even though the clinical applications are not presently valid yet.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives.

M onitoring of pulmonary function and timely initiation of noninvasive ventilation should be a focus in supportive care for patients with muscular disorders. In the current issue of the European Respiratory Journal, PELLEGRINI et al. [1] focus on this aspect in patients with lateonset Pompe disease (glycogenosis type II, acid maltase deficiency) [1]. In Pompe disease, correct monitoring of pulm...

متن کامل

S3.2 The role of Patients Association (Italian Glycogenosis Association)

(the only available biomarker of muscle glycogenosis type II) and brain MRI if there are symptoms suggestive of CNS involvement. In conclusion, being available the ERT therapy, it is really important to diagnose Pompe disease as soon as possible to avoid respiratory and skeletal muscle degeneration. Group Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enz...

متن کامل

State of the art in muscle glycogenoses

The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe dise...

متن کامل

Clinical guidelines for late-onset Pompe disease.

Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe dise...

متن کامل

Pompe practice survey of Canadian (Ontario) rheumatologists

Introduction Pompe disease (glycogenosis II, acid maltase deficiency, OMIM 232300) is a treatable autosomal recessive disorder of glycogen metabolism caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. A hallmark of Pompe disease is the presence of glycogen-loaded lysosomes. Pompe disease has frequently been misdiagnosed as other myopathies, such as polymyositis, and mistakenly...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Revue medicale de Liege

دوره 54 3  شماره 

صفحات  -

تاریخ انتشار 1999